Lubricin-inspired Osteoarthritis Treatment: a Unique Solution

This goal of this open label study is to evaluate the safety and tolerability of a single intra-articular administration of ABR1 in adults with knee osteoarthritis with a KL grade from 2 to 4. The primary questions it aims to answer are: 1. Is ABR1 safe to use as an intraarticular injection for participants with knee osteoarthritis? 2. What medical problems do participants have after receiving a single injection of ABR1? Participants will receive a single injection of ABR1 to the knee with osteoarthritis. Participants will 1. Keep a stable pain treatment regimen 2. Visit the clinic at 1 week, 4 weeks, 8 weeks, and 12 weeks post injection 3. Keep a diary of their symptoms and number of times they use a rescue medication for their knee pain.

NCT Number	NCT07611708
Lead Sponsor	Pleryon Therapeutics (Hangzhou) Limited
Conditions	Osteo Arthritis of the Knee
Enrollment	25 participants
Start Date	2026-08
Primary Completion	2027-06 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2026-05-29